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Sonographically Guided Knee Meniscus Injections: Feasibility,
Techniques, and Validation
Michael R. Baria, MD/MBA, Jacob L. Sellon, MD, Dan Lueders, MD, Jay Smith, MDAbstractBackground: There is a growing interest in the use of biologic agents such as platelet-rich plasma and mesenchymal stem/stromal
cells to treat musculoskeletal injuries, including meniscal tears. Although previous research has documented the role of diag-
nostic ultrasound to evaluate meniscal tears, sonographically guided (SG) techniques to specifically deliver therapeutic agents
into the meniscus have not been described.
Objective: To describe and validate SG injection techniques for the body and posterior horn of the medial and lateral meniscus.
Design: Prospective, cadaveric laboratory investigation.
Setting: Academic institution procedural skills laboratory.
Subjects: Five unenbalmed cadaveric knee-ankle-foot specimens from 5 donors (3 female and 2 male) ages 33-92 years (mean age
74 years) with body mass indices of 21.1-32.4 kg/m2 (mean 24.1 kg/m2).
Methods: A single, experienced operator completed SG injections into the bodies and posterior horns of the medial and lateral
menisci of 5 unenbalmed cadaveric knees using colored latex and a 22-gauge, 38-mm needle. After injection, coinvestigators
dissected each specimen to assess latex distribution within the menisci and identify injury to intra-articular and periarticular
structures.
Main Outcome Measures: Latex location within the target region of meniscus (accurate/inaccurate), and iatrogenic injury to “at
risk” intra- and periarticular structures (present/absent).
Results: Seventeen of 20 injections were accurate. Two of 3 inaccurate injections infiltrated the posterior horn of the medial
meniscus instead of the targeted meniscal body. One inaccurate lateral meniscus injection did not contain latex despite sono-
graphically accurate needle placement. No specimen exhibited injury to regional neurovascular structures or intra-articular
hyaline cartilage.
Conclusions: SG meniscus injections are feasible and can accurately and safely deliver injectates such as regenerative agents into
bodies and posterior horns of the medial and lateral menisci. The role of SG intrameniscal injections in the treatment of patients
with degenerative and traumatic meniscal disorders warrants further exploration.
Level of Evidence: Not applicable.Introduction
Knee meniscal injuries are very common, may
significantly impact function, and predispose the knee
to accelerated osteoarthritis [1]. The body and posterior
horn of the meniscus are particularly susceptible to
acute injury and chronic degeneration [2]. Symptomatic
meniscal tears may be treated with activity modifica-
tion, modalities, bracing, therapeutic exercise, intra-
articular injections and, when clinically indicated,
surgical debridement or repair [3].
In recent years, there has been increased interest in
the use of biologic agents (eg, platelet-rich plasma,1934-1482/$ - see front matter ª 2017 by the American Academy of Physi
http://dx.doi.org/10.1016/j.pmrj.2016.12.012bone marrow aspirate concentrate, and mesenchymal
stem/stromal cells [MSCs]) to treat patients suffering
from a variety of musculoskeletal disorders, including
tendinosis, osteoarthritis, and meniscal tears [4,5].
Vangsness et al [6] found that a single, postoperative
intra-articular injection of culture expanded, alloge-
neic, bone marrowderived MSCs was well tolerated,
improved pain, and promoted meniscal regeneration in
patients after arthroscopic debridement of degenera-
tive meniscal tears. Multiple authors also have reported
therapeutic benefits from direct placement of biologic
agents (eg, fibrin clots, stem cell-scaffold combinations)
into the meniscus as an adjunct to arthroscopic surgerycal Medicine and Rehabilitation
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expanded, autologous, bone marrowderived MSCs also
may improve symptoms and possibly promote meniscal
regeneration in the context of nonoperative treatment
programs for degenerative meniscal tears [9], the
feasibility of percutaneous intrameniscal delivery of
biologic agents has not been explored previously.
The ability of high-resolution ultrasound (US) to
image the meniscus has been well-established [10-12];
however, the feasibility of using sonographic guidance
(SG) to specifically deliver needles/injectates into the
bodies and posterior horns of the medial and lateral
menisci has not been evaluated formally. Consequently,
the primary purpose of this investigation was to deter-
mine the feasibility of SG intrameniscal injections; more
specifically, to determine the safety and accuracy of SG
body and posterior horn intrameniscal injections by
using an unembalmed cadaveric model. We hypothe-
sized that SG could be used to accurately and safely
place a standard 22-gauge needle into the bodies and
posterior horns of the medial and lateral menisci. Clin-
ically, the results of this investigation would provide a
foundation for the clinical implementation of SG intra-
meniscal injections in appropriately selected patients.
MethodsGeneral DesignA single, experienced operator (the corresponding
author) injected 0.5-1.0 mL of colored latex dye (Ward’s
Biological Science, Rochester, NY) into the bodies and
posterior horns of both the medial and lateral menisci in
5 unembalmed, cadaveric knee-ankle-foot specimens
using direct SG and a 22-gauge, 38-mm needle. At the
time of the investigation, the operator had more than 12
years of experience in diagnostic and interventional
musculoskeletal US, including SG knee injections. All
specimens were obtained from the Department of
Anatomy’s Foundation Bequest Program and were free
from deformity, signs of trauma, and postsurgical
change. Study coinvestigators dissected each specimen
to determine the accuracy of intrameniscal latex in-
jection as well as the presence or absence of iatrogenic
injury to the regional neurovascular structures and
intra-articular hyaline cartilage. This investigation was
approved by the Bio-Specimens Subcommittee of the
Institutional Review Board at the authors’ institution
(Institutional Review Board no. 14-005967).EquipmentAll imaging and injections were completed with a
Philips iU22 ultrasound machine and a 12-5 MHz linear
array transducer (Philips Ultrasound Systems, Bothell,
WA). All injections were completed with standard
22-gauge, 38-mm stainless-steel needles.Injection ProcedureEach specimen was placed in a side-lying position
with the target side of the knee facing the ceiling. To
optimize sonographic visualization and meniscal access,
the knee was flexed to 30-60 and a gravity-induced
valgus or varus stress was imparted on the joint by
placing a small, rolled-up towel under the dependent
side of the knee [11]. The transducer was then placed in
an anatomical coronal plane across the joint, perpen-
dicular to the long axis (LAX) of the meniscus, yielding a
short-axis view (or cross-section) of the meniscus.
Thereafter, the regional “at-risk” structures were
identified sonographically and their locations were
marked with an indelible ink markerdthe saphenous
nerve medially and the common fibular nerve laterally.
The medial and lateral meniscal body injections were
conducted via a similar technique. After identification
of the regional “at-risk” structures, the meniscal body
was reidentified in the coronal plane (short-axis
meniscal view). For the medial meniscal body, a 22-
gauge, 38-mm stainless-steel needle was then
advanced with a SG, out-of-plane, anterior-to-posterior
approach. During the first 3 injections, the needle entry
point and trajectory were chosen primarily based on
avoiding the saphenous nerve. However, after the
documentation of 2 inaccurate injections placed into
the posterior horn (as described in the Results section),
the medial meniscal body injection technique was
modified to use the medial collateral ligament (MCL) as
a consistent landmark. For these subsequent injections,
the transducer was placed in the coronal plane just
anterior to the MCL to facilitate consistent needle and
latex placement into the body of the medial meniscus
using the out-of-plane approach. Once the needle tip
was visualized within the meniscal body, the transducer
was rotated 90 into the anatomical axial plane, yielding
an LAX view of the meniscus and an in-plane view of the
needle (Figure 1). The needle was advanced to the
innermost/deepest portion of the meniscal body using
direct SG and an in-plane approach. After final needle
placement, the operator injected 0.5-1.0 mL of colored
latex dye into the meniscus as the needle was with-
drawn. The lateral meniscal body was injected via a
similar technique, with the transducer placed in an
anatomical coronal plane at the level of popliteus
sulcus.
To inject the posterior horns of the menisci, the
meniscal body initially was identified as described pre-
viously. Thereafter, the transducer was translated pos-
teriorly over the region of the posterior horn. However,
in contrast to the meniscal body injection technique,
before needle entry the transducer was rotated to
provide a LAX view of the posterior horn. Pilot in-
vestigations had indicated that visualizing the posterior
horn in its LAX throughout the procedure facilitated
identification and maintenance of the necessary
Figure 1. (A) Setup for a SG out-of-plane right medial meniscus body injection showing probe and needle position in an unembalmed cadaveric
specimen. (B) Short-axis view of the medial meniscus body (hollow yellow arrow) demonstrating a medial meniscus body injection with a 22-gauge
stainless-steel needle. The needle (solid yellow arrow) is initially positioned using an out-of-plane approach, entering anterior to the MCL
(asterisks) and advanced posteriorly. (C) Setup for medial meniscus body injection after probe rotation into a long-axis view of the medial
meniscus and in-plane view of the needle. (D) Long-axis view of the medial meniscus body (hollow yellow arrow) and an in-plane view of the
needle (solid yellow arrows). ANT ¼ anterior; FEM ¼ femur; IA ¼ intra-articular space; MCL ¼ medial collateral ligament; POST ¼ posterior; SQ ¼
subcutaneous tissue; TIB ¼ tibia.
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of the posterior horn. After sonographic visualization of
the posterior horn, a 22-gauge, 38-mm stainless-steel
needle was advanced using an in-plane, anterior-to-
posterior approach. The needle tip was advanced to the
deepest visible aspect of the posterior horn (Figure 2)
and 0.5-1.0 mL of latex dye was injected as the needle
was withdrawn.
After each injection, coinvestigators dissected the
specimen to determine injection accuracy and assess forFigure 2. (A) Setup for a SG in-plane right lateral meniscus posterior ho
cadaveric specimen. (B) LAX view of the lateral meniscus posterior horn (h
steel needle (solid yellow arrows). Needle is advanced in an anterolatera
ligament (anisotropic). ALAT ¼ anterolateral; PMED ¼ posteromedial; SQ ¼iatrogenic injury to the regional “at-risk” structures.
Accuracy was scored as either “accurate” (a clear track
of latex dye within the targeted meniscus region) or
“inaccurate” (no clear track seen within the targeted
meniscus region). Qualitative observations included the
quality of latex spread within the target region, the
presence of latex overflow into adjacent regions, and
the presence of iatrogenic injury to the regional “at-
risk” structures including the saphenous nerve, common
fibular nerve, lateral inferior geniculate artery, andrn injection, showing probe and needle position in an unembalmed
ollow yellow arrow) demonstrating injection with a 22-gauge stainless
l to posteromedial direction. Asterisk indicates the posterior cruciate
subcutaneous tissue; TIB ¼ tibia.
1001M.R. Baria et al. / PM R 9 (2017) 998-1005intra-articular hyaline cartilage. All outcomes were
graded by a consensus of 2 coinvestigators. Results were
summarized with descriptive statistics.Figure 3. Superior view of the medial meniscus demonstrating an
accurately placed latex trail in the posterior horn (PH); however, the
meniscal body injection (B) was placed too far posteriorly and there-
fore was considered inaccurate. The injection technique was subse-
quently modified to prevent this “overshoot” by placing the transducer
just anterior to the MCL (solid yellow arrow, see text for explanation).
Top ¼ posterior; Bottom ¼ anterior; Left ¼medial/superficial; Right ¼
lateral/deep.Results
A total of 20 SG intrameniscal injections were per-
formed in 5 unembalmed cadaveric knees from 5 donors
(3 male, 2 female) ages 33-92 years (mean 74 years) and
body mass indices of 21.1-32.4 kg/m2 (mean 24.1 kg/
m2). Sonographic visualization of the meniscal body and
posterior horn, saphenous nerve, and common fibular
nerve was satisfactory in all specimens. Not unexpect-
edly, sonographic visualization of the lateral inferior
geniculate artery was not possible in all specimens
because of the absence of pulsatile blood flow. Needle
visualization was excellent in all specimens and 2 gen-
eral injection flow patterns were observed: (1) high
resistance flow, in which latex distribution was more
discrete and limited to the needle track, and (2) low
resistance flow, in which the latex distribution was more
irregular and extended into the meniscus beyond the
needle track. Although formal sonographic assessment
of meniscal status was not performed as part of this
investigation, the former flow pattern was more com-
mon in normal menisci, whereas the latter was observed
in association with degenerative changes and/or
meniscal clefts potentially representing tears.
Injection accuracy is presented in Table 1. Seventeen
of 20 injections were accurate. Two of the 3 inaccurate
injections were medial meniscal body injections in
which the latex was placed more posteriorly than
desireddin the region of the posterior horn (Figure 3).
This was determined to result from initial placement of
the transducer just superficial to the MCL. With this
transducer placement, during the out-of-plane needle
approach the needle had a tendency to pass too far
posteriorly (ie, out of the region of the body and into
the region of the posterior horn) by the time it reached
its target depth. This technical limitation was resolved
by placing the transducer anterior to the MCL during





















Total 17 (85%) 3 (15%)inaccurate injection was a lateral meniscus body in-
jection in which no latex was seen in the meniscus. No
specimens demonstrated evidence of iatrogenic injury
to the saphenous nerve, common fibular nerve, lateral
inferior geniculate artery, or intra-articular hyaline
cartilage.Discussion
The most important finding of this investigation was
that SG intrameniscal injections are feasible and can
safely place injectates into the bodies and posterior
horns of the medial and lateral menisci with acceptable
accuracy. Consequently, the current results provide a
foundation for consideration of SG intrameniscal
injections in clinically appropriate populations.
Improving pain and function in patients with symp-
tomatic degenerative or traumatic meniscal tears con-
tinues to challenge clinicians. Although surgical
intervention is clearly indicated in selected cases, sur-
gery is not without consequences. For example, Roos
et al [13] demonstrated that when compared with age-
matched controls with healthy knees, patients treated
with total meniscectomy had a relative risk of 14.0 for
developing advanced radiographic findings of osteoar-
thritis and a 2-fold increased risk of developing clinically
significant knee pain at a mean of 21 years postsurgery.
These and similar findings have fostered the philosophy
of meniscal preservation when managing symptomatic
meniscal disorders. For example, multiple studies have
emphasized the clinical and biomechanical benefits of
partial versus total meniscectomy [14,15].
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consequence. A prospective, randomized trial by Hede
et al [16] demonstrated that only 62% of patients
treated with partial meniscectomy had an excellent
outcome at a median 7.8 years’ follow-up, which was
not statistically significantly different from the 52%
excellent outcome in the total meniscectomy group.
Consequently, as the evidence in support of meniscal
preservation has accumulated, a variety of meniscal
repair techniques have evolved to avoid or minimize the
extent of meniscal resection. Many of these techniques
have been augmented successfully by intraoperative
biologic treatments such as fibrin clot application,
trephination, meniscocapsular abrasion, and more
recently application of cell-based therapies and scaf-
folds [7,8]. The primary goal of these adjunctive bio-
logic treatments is to facilitate healing and preserve or
perhaps regenerate the meniscus.
Although the intraoperative application of biologic
agents in the treatment of meniscal tears is well
established, the use of biologic agents as an adjunct to
nonoperative meniscus tear treatment has been limited
to a few select case reports [9]. One potential expla-
nation for this discrepancy is the inability to precisely
deliver the desired biologic agent into the meniscus in
the absence of direct intraoperative visualization. As
demonstrated in the current study, high-resolution US
can fill this void by facilitating precise and accurate
needle placement into the bodies and posterior horns of
the medial and lateral menisci, the most common re-
gions associated with acute and chronic symptomatic
meniscal tears [2]. Consequently, the role of SG intra-
meniscal injections can now be explored via future
research and collective clinical experience.
There are several limitations and technical factors
that warrant further discussion in the context of the
current study. First, clinicians should exercise appro-
priate caution when extrapolating the results of this
cadaveric investigation to clinical scenarios. Although
the current study documents the feasibility of SG
meniscal injections, we are unable to comment on the
clinical efficacy of intrameniscal injections with respect
to specific therapeutic agents or the role of intra- versus
extrameniscal injections in specific clinical circum-
stances. With respect to safety, we did not directly
visualize the lateral inferior geniculate artery due to
lack of Doppler flow. Although this artery can be easily
visualized on US and therefore avoided when performing
SG lateral meniscal injections, the current study design
precludes definitive statements pertaining to the safety
of SG injections with respect to the perimeniscal
vasculature.
Second, we used a 22-gauge, 38-mm stainless-steel
needle to accommodate the viscosity of the latex. We
recognize that some therapeutic agents may have
higher or lower viscosities that will influence the choice
of needle gauge and the propensity for injectate spreadfrom the target site postinjection. A low-viscosity
injectable can be delivered via a small-gauge needle,
thus minimizing inadvertent tissue trauma; however,
the therapeutic agent may have a tendency to migrate
from the target site. In comparison, a greater viscosity
agent may more likely remain at the target site but
would require a larger gauge needle and potentially
incur additional risk of inadvertent tissue trauma. In
addition to the needle gauge, we acknowledge the po-
tential differences in viscosity between latex used in
this study and that of various biologic agents used in
clinical practice. That said, the purpose of this study
was to validate injection technique. We used latex
because of previous experience using this model in
cadaveric studies. The advantages of latex for the study
include ease of use and the ability to define a clear in-
jection deposit on dissection. We recognize that the
viscosity of latex may not be the same as biologic agents
used in practice. There is no standard viscosity for
various biologics because they may vary between pa-
tients and among different preparations. Therefore, it is
impractical to test the flow characteristics of the “bi-
ologics” in the presented model. This limitation does
not limit the applicability of the described injection
technique. Operators will need to consider all these
factors during any clinical application of SG meniscal
injections.
Third, we reported 3 inaccurate injections, 2 of
which resulted from technical factors that were miti-
gated by procedural changes as previously described
(ie, placing the transducer anterior to rather than su-
perficial to the MCL for the medial meniscus body in-
jection). The reason for the third inaccurate injection
remains indeterminate but may have resulted from the
high latex viscosity. In the setting of normal menisci,
which was the case with respect to the specimen in
question, the latex injection required high injection
pressure due to the densely packed meniscal fibers.
Although the latex was “injected” as the needle was
withdrawn, the flow of latex into the needle track could
not be directly sonographically visualized in all cases.
The use of small injection volumes and the compress-
ibility of the latex solution further limited the ability to
unequivocally confirm the actual delivery of intra-
meniscal latex during the injection. Consequently, we
hypothesize that despite accurate needle placement as
evidenced by the anatomically identified needle track,
it is probable that no latex was in fact injected into the
lateral meniscus in this case. We also recognize the less
likely possibility that some latex was initially injected
into the meniscus but subsequently flowed back out of
the needle track as the result of high intrameniscal
pressures. In either case, the lack of latex within the
meniscus does not reflect a limitation of the SG intra-
meniscal injection since the needle was in fact placed
accurately. Furthermore, from a clinical perspective,
operators should not encounter these technical
Figure 5. Superior view of the lateral meniscus body. Similar to
Figure 4, the meniscus has been incised parallel to its long axis and the
superior aspect of the meniscus body reflected to reveal the accurate
meniscal body injection (solid yellow arrow). In comparison with
Figure 4, this meniscus was grossly normal and the latex spread was
therefore restricted to the needle track. Note also the staining from
the accurately placed posterior horn (PH) injection in this specimen
(hollow yellow arrows). Left ¼ deep/medial; Right ¼ superficial/
lateral; Top ¼ posterior; Bottom ¼ anterior; AH ¼ anterior horn;
B ¼ body.
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chronic tears, where low pressure distribution of the
injectate is likely to be observed (Figure 4 versus
Figures 5, 6, and 7).
Fourth, from our dissections it is clear that SG can be
used to deliver injectates across the full width of the
meniscus, including the innermost portion of the body
(the white-white zone) and the root of the posterior
horn (Figures 6 and 8, respectively). Therefore, SG
intrameniscal injections could be considered to accu-
rately deliver biologics to the avascular regions of the
meniscus with poor spontaneous healing potential [17].
Fifth, the lateral meniscus was technically more
difficult to inject than the medial meniscus because of
its greater mobility. Specifically, as the needle was
being placed into and advanced through the lateral
meniscus, the meniscus often moved considerably.
Meniscal degeneration or tearing may accentuate this
phenomenon. Identifying mitigation strategies for this
undesirable movement will require further investigation
and experience.
Sixth, as exhibited in several of our specimens,
injectate flow beyond the confines of the meniscus is
possible and perhaps in some cases expected (Figures 4
and 7). Although the clinical significance of extra-
meniscal extension remains unknown and probably is
dependent on the specific clinical scenario, extra-
meniscal extension can be minimized by precise needle
placement and control facilitated by (1) practice in
cadaveric specimens when available, (2) confirmation of
needle tip position in 2 orthogonal planes, (3) avoidance
of needle passage beyond the sonographically identified
limits of the meniscus, (4) control of injection volume,Figure 4. Superior view of medial meniscus posterior horn (PH). The
PH has been incised longitudinally and the superior half reflected to
reveal the full injection pathway. Note the distribution of latex within
the PH. This meniscus exhibited structural changes consistent with
degenerative meniscal tearing. Consequently, the latex spread
throughout the region of degeneration. Left ¼ superficial/medial;
Right ¼ deep/lateral; Top ¼ anterior; Bottom ¼ posterior; AH ¼
anterior horn; B ¼ body.and (5) the use of identifiable anatomical landmarks
during the setup and execution of the procedure.
With respect to the latter recommendation, the
anterior aspect of the MCL and the popliteal sulcus
proved to be reliable landmarks for transducer place-
ment and needle entry during medial and lateral body
injections, respectively, whereas the posterior cruciate
ligament (PCL) also can be used to facilitate identifi-
cation of the posterior horns of the menisci and if
desired, the posterior roots [18]. The PCL initially is
identified in an anatomical oblique sagittal plane andFigure 6. Cross-sectional view of the lateral meniscus posterior horn
showing an accurate injection pathway. The specimen has been
dissected to specifically demonstrate the posterior root (PR) of the
lateral meniscus. The body and anterior horn have been resected to
produce a meniscal cross section at the junction of body and posterior
horn (asterisk), and a portion of the inner third (ie, white-white zone)
of the posterior horn has been removed to demonstrate the injection
track. Similar to the specimen in Figure 5, this meniscus was grossly
normal, thus limiting latex flow to within the confines of the needle
track (compare with Figure 4). Left ¼ deep/medial; Right ¼ superfi-
cial/lateral; Top ¼ cranial; Bottom ¼ caudal.
Figure 7. Inferior view of the medial meniscus showing accurate latex
deposition into both the body (B) and posterior horn (PH) regions.
Similar to the specimen in Figure 4, this specimen exhibited degen-
erative changes in the body and posterior horns. The distribution of
latex within the middle and inner thirds of the meniscus reflect
accurate needle placement into these regions as described in the
Methods. Note the extension of latex outside of the confines of the
meniscus, which was observed in several specimens (See text for dis-
cussion). Left ¼ superficial/medial; Right ¼ deep/lateral; Top ¼
anterior; Bottom ¼ posterior; AH ¼ anterior horn.
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the side of interest. The posterior horn of the meniscus
is the first soft-tissue, intra-articular structure seen in
the tibiofemoral joint after translating medially or
laterally off of the PCL. Once the posterior horn is
identified, the transducer is rotated 90 into the
anatomical axial plane, yielding a LAX view of the pos-
terior horn.
Seventh, all injections in the current investigation
were performed by a single experienced operator.
Although the techniques described herein have been
easily taught to less-experienced operators, interoper-
ator reliability was not investigated formally in this
study. Finally, it is unknown whether there is anyFigure 8. Cross-sectional view of medial meniscus body showing
injectate deposition into middle (ie, red-white zone) and inner thirds
(ie, white-white zone) of the meniscus. Top ¼ superior; Bottom ¼
inferior; Left ¼ lateral/deep; Right¼ medial/superficial; R ¼ red-red
zone; W ¼ white-white zone.clinically relevant iatrogenic injury associated with this
technique. Meniscal trephination using an 18-gauge
needle is a well-described, long-accepted operative
technique to facilitate meniscal healing, and the tech-
nique described in this study is similar in principle [19].
Given that primum non nocere remains a guiding prin-
ciple, this technique should be applied targeting only
damaged tissue and using SG so as to minimize the
extent of normal tissue traversed.Conclusions
SG intrameniscal injections are technically feasible
and should be considered when clinically indicated.
Further research and clinical experience is necessary to
clarify the role of SG intrameniscal injections to reduce
pain, improve function, and preserve or regenerate the
meniscus in patients with symptomatic acute or chronic
degenerative meniscal tears.Acknowledgments
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